Drug: Epclusa (ep-KLOO-suh)
Epclusa is a combination of two drugs—sofosbuvir, a polymerase inhibitor and velpatasvir, a NS5A inhibitor, combined into one pill, taken once-a-day.Epclusa is taken with or without food. Epclusa is approved by the Food and Drug Administration to treat adults infected with chronic hepatitis C (HCV) genotype 1, 2, 3, 4, 5 and 6.It can be taken with and without ribavirin. Epclusa is manufactured by Gilead Sciences Inc.
The overall cure rates of Epclusa are up to and over 90%.The wholesale acquisition cost (WAC) for Epclusa is $74,760.00 for a ...
Drug: Daklinza (dak lin za)
Daklinza is an NS5A inhibitor (daclatasvir) that is approved only in combination with another drug — Sovaldi a polymerase inhibitor (sofosbuvir) — to treat chronic hepatitis C genotype 1 and 3 infections. It is limited to treated just certain conditions. It can be taken with and without ribavirin. Daklinza is manufactured by Bristol-Myers Squibb. Sovaldi is manufactured by Gilead Sciences Inc.
The overall cure rates of Daklinza plus sofosbuvir are up to and over 90%. The wholesale acquisition cost (WAC) for Daklinza is $64,000 for a 12-week ...
Drug: Sovaldi (soh-VAHL-dee)
Sovaldi is a polymerase inhibitor that is taken in combination with ribavirin. It is taken once-a-day with or with or without food. Sovaldi is approved by the Food and Drug Administration (FDA) to treat adults infected with hepatitis C (HCV) genotype 2 and 3. Sovaldi is manufactured by Gilead Sciences Inc. Note: Sovaldi is also approved in combination pegylated interferon to treat genotype 1 and 4. This review will only discuss Sovaldi plus ribavirin to treat genotype 2 and 3.
Initial FDA Approval: 2013
The wholesale acquisition cost (WAC) for ...